TY - JOUR
T1 - Frequency of cancer testis antigens in chronic myeloid leukemia
AU - Mendoza-Salas, I.
AU - Olarte-Carrillo, I.
AU - Miranda-Peralta, E.
AU - Ramos-Peñafiel, C.
AU - García-Laguna, A.
AU - Cerón-Maldonado, R.
AU - De la Cruz-Rosas, A.
AU - Collazo-Jaloma, J.
AU - Kassac-Ipiña, J.
AU - Mendoza-García, E.
AU - Ramón-Gallegos, E.
AU - Martínez-Tovar, A.
N1 - Publisher Copyright:
© 2015 Sociedad Médica del Hospital General de México.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Background: Cancer testis antigens (CTA) are expressed in several types of cancer but not in normal adult tissue, with the exception of testicular germ cells, and for this reason are considered targets for immunotherapy. Objective: The aim of this study was to determine the frequency and clinical significance of CTA expression in cells from patients with chronic myeloid leukaemia (CML). Materials and methods: We analysed 8 genes of the CTA family (MAGE-A3, MAGE-A4, MAGE-B2 MAGE-C1, BAGE-1, GAGE-2, LAGE-1 and NY-ESO-1) in 10 peripheral blood samples from healthy donors and 65 bone marrow samples from CML patients using reverse transcriptase polymerase chain reaction (RT-PCR). Eleven samples from hematopoietic progenitor stem cells from patients receiving conventional treatment (hydroxyurea and INFα) and 21 samples from patients receiving tyrosine kinase inhibitors (Imatinib, Nilotinib, Dasatinib) were analysed. Results: Frequency of CTA genes in CML patients was 32.3%, 63.0%, 1.5%, 3.0%, 6.1%, 20.0%, 13.8% and 36.9% for MAGE-A3, MAGE-A4, MAGE-B2, MAGE C1, BAGE, GAGE, LAGE and NY-ESO, respectively. The correlation between expression and clinical parameters showed statistical significance in the MAGE-A3 genes in sex (p = 0.018), MAGE-C1 in leukocytes (p = 0.014) in platelets (p = 0.002), and finally LAGE-1, which was associated with platelets (p = 0.001). The hematopoietic progenitor stem cells from patients in treatment showed a higher frequency of expression than de novo patients. In patients receiving conventional drugs (CD), frequency of MAGE-A3 expression was 50%, and 69.2% with TKI, MAGE-A4 frequency was 20% with CD and53.8% with TKI. Finally, frequency of NY-ESO-1 was 20% with CD and 0% with TKI. The frequency of MAGE-A4 expression was highest, followed by MAGE-A3, NY-ESO-1, GAGE-2, LAGE-1, BAGE-1,MAGE-B2 and MAGE-C1.Conclusion: Detection of CTA genes by molecular biology techniques is important due to their use as biomarkers in LMC, in the monitoring of disease progression and in patients who are resistant to chemotherapy. The frequency of CTA expression in treated and de novo differs significantly.
AB - Background: Cancer testis antigens (CTA) are expressed in several types of cancer but not in normal adult tissue, with the exception of testicular germ cells, and for this reason are considered targets for immunotherapy. Objective: The aim of this study was to determine the frequency and clinical significance of CTA expression in cells from patients with chronic myeloid leukaemia (CML). Materials and methods: We analysed 8 genes of the CTA family (MAGE-A3, MAGE-A4, MAGE-B2 MAGE-C1, BAGE-1, GAGE-2, LAGE-1 and NY-ESO-1) in 10 peripheral blood samples from healthy donors and 65 bone marrow samples from CML patients using reverse transcriptase polymerase chain reaction (RT-PCR). Eleven samples from hematopoietic progenitor stem cells from patients receiving conventional treatment (hydroxyurea and INFα) and 21 samples from patients receiving tyrosine kinase inhibitors (Imatinib, Nilotinib, Dasatinib) were analysed. Results: Frequency of CTA genes in CML patients was 32.3%, 63.0%, 1.5%, 3.0%, 6.1%, 20.0%, 13.8% and 36.9% for MAGE-A3, MAGE-A4, MAGE-B2, MAGE C1, BAGE, GAGE, LAGE and NY-ESO, respectively. The correlation between expression and clinical parameters showed statistical significance in the MAGE-A3 genes in sex (p = 0.018), MAGE-C1 in leukocytes (p = 0.014) in platelets (p = 0.002), and finally LAGE-1, which was associated with platelets (p = 0.001). The hematopoietic progenitor stem cells from patients in treatment showed a higher frequency of expression than de novo patients. In patients receiving conventional drugs (CD), frequency of MAGE-A3 expression was 50%, and 69.2% with TKI, MAGE-A4 frequency was 20% with CD and53.8% with TKI. Finally, frequency of NY-ESO-1 was 20% with CD and 0% with TKI. The frequency of MAGE-A4 expression was highest, followed by MAGE-A3, NY-ESO-1, GAGE-2, LAGE-1, BAGE-1,MAGE-B2 and MAGE-C1.Conclusion: Detection of CTA genes by molecular biology techniques is important due to their use as biomarkers in LMC, in the monitoring of disease progression and in patients who are resistant to chemotherapy. The frequency of CTA expression in treated and de novo differs significantly.
KW - Cancer testis antigens
KW - Chronic myeloid leukaemia
KW - MAGE
UR - http://www.scopus.com/inward/record.url?scp=85043663914&partnerID=8YFLogxK
U2 - 10.1016/j.hgmx.2015.10.003
DO - 10.1016/j.hgmx.2015.10.003
M3 - Artículo
SN - 0185-1063
VL - 79
SP - 46
EP - 54
JO - Revista Medica del Hospital General de Mexico
JF - Revista Medica del Hospital General de Mexico
IS - 2
ER -
